A systematic review and economic model of the effectiveness and ...

134
References
24. Crystal DS, Ostrander R, Chen RS, August GJ.
Multimethod assessment of psychopathology
among DSM-IV subtypes of children with
attention-deficit/hyperactivity disorder: self-,
parent, and teacher reports. J Abnorm Child Psychol
2001;29:189–205.
25. Datapharm Communications. Electronic
Medicines Compendium (eMC): summary of
product characteristics. URL:
http://emc.medicines.org.uk/. Accessed 18
November 2004.
26. Janssen-Cilag. Putting patients at the heart of
everything we do. High Wycombe: Janssen-Cilag
Limited: Bucks; 2004. URL: http://www.janssencilag.co.uk/index.asp.
Accessed 9 December 2004.
27. Healthyplace. Atomoxetine HCl. Brand name:
Strattera. 2002. URL:
http://www.healthyplace.com/medications/strattera.
htm. Accessed 9 December 2004.
28. Jadad AR, Boyle M, Cunningham C, Kim M,
Schachar R. Treatment of attention-deficit/hyperactivity
disorder. Evidence Report: Technology Assessment
No. 11. Rockville, MD: Agency for Health Care
Policy and Research; 1999.
29. Joint Formulary Committee. British National
Formulary. 47th ed. London: British Medical
Association and the Royal Pharmaceutical Society
of Great Britain; 2004.
30. Canadian Coordinating Office for Health
Technology Assessment (CCOHTA). A review of
therapies for attention-deficit/hyperactivity disorder –
systematic review. Ottawa: Canadian Coordinating
Office for Health Technology, Assessment
(CCOHTA), 1998. URL: http://www.ccohta.ca
31. Centre for Reviews and Dissemination. CRD Report
No. 4. Undertaking systematic reviews of research on
effectiveness: CRD’s guidance for those carrying out or
commissioning reviews. 2nd ed. York: Centre for
Reviews and Dissemination; 2001.
32. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E,
Greenhill LL, Biederman J, et al. A comparison of
once-daily extended-release methylphenidate
formulations in children with attentiondeficit/hyperactivity
disorder in the laboratory
school (the Comacs Study). Pediatrics
2004;113:e206–16.
33. Elbourne DR, Altman DG, Higgins JP, Curtin F,
Worthington HV, Vail A. Meta-analyses involving
cross-over trials: methodological issues. Int J
Epidemiol 2002;31:140–9.
34. Drummond M, Jefferson T. Guidelines for authors
and peer reviewers of economic submissions to
BMJ. BMJ 1996;313:275–83.
35. Ahmann PA, Waltonen SJ, Olson KA, Theye FW,
van Erem AJ, LaPlant RJ. Placebo-controlled
evaluation of ritalin side effects. Pediatrics
1993;91:1101-6.
36. Arnold LE, Huestis RD, Smeltzer DJ, Scheib J,
Wemmer D, Colner G. Levoamphetamine vs
dextroamphetamine in minimal brain dysfunction.
Replication, time response, and differential effect
by diagnostic group and family rating. Arch Gen
Psychiatry 1976;33:292–301.
37. Arnold LE, Christopher J, Huestis R, Smeltzer DJ.
Methylphenidate vs dextroamphetamine vs
caffeine in minimal brain dysfunction: controlled
comparison by placebo washout design with Bayes’
analysis. Arch Gen Psychiatry 1978;35:463–73.
38. Arnold LE, Kleykamp D, Votolato NA, Taylor WA,
Kontras SB, Tobin K. Gamma-linolenic acid for
attention-deficit hyperactivity disorder: placebocontrolled
comparison to D-amphetamine. Biol
Psychiatry 1989;25:222–8.
39. Barkley RA, McMurray MB, Edelbrock CS,
Robbins K. Side effects of methylphenidate in
children with attention deficit hyperactivity
disorder: a systematic, placebo-controlled
evaluation. Pediatrics 1990;86:184–92.
40. Barkley RA, Connor DF, Kwasnik D. Challenges to
determining adolescent medication response in an
outpatient clinical setting: comparing Adderall
and methylphenidate for ADHD. J Atten Disord
2000;4:102–13.
41. Brown RT, Wynne ME, Medensis R.
Methylphenidate and cognitive therapy: a
comparison of treatment approaches with
hyperactive boys. J Abnorm Child Psychol
1985;13:69–87.
42. Brown RT, Wynne ME, Boren KA, Clingerman SR,
Geniesse R, Spunt AL. Methylphenidate and
cognitive therapy in children with attention-deficit
disorder: a double-blind trial. J Dev Behav Pediatr
1986;7:163–74.
43. Brown RT, Sexton SB. A controlled trial of
methylphenidate in black adolescents. Attentional,
behavioural, and physiological effects. Clin Pediatr
1988;27:74–81.
44. Buitelaar JK, van der Gaag R, Swaab-Barneveld H,
Kuiper M. Pindolol and methylphenidate in
children with attention-deficit hyperactivity
disorder: clinical efficacy and side-effects. J Child
Psychol Psychiatry 1996;37:587–95.
45. Conners CK, Taylor E, Meo G, Kurtz MA, Fournier
M. Magnesium pemoline and
dextroamphetamine: a controlled study in
children with minimal brain dysfunction.
Psychopharmacologia 1972;26:321–36.
46. Conners CK, Taylor E. Pemoline,
methylphenidate, and placebo in children with
minimal brain dysfunction. Arch Gen Psychiatry
1980;37:922–30.
47. Conrad WG, Dworkin ES, Shai A, Tobiessen JE.
Effects of amphetamine therapy and prescriptive